Purpose: The aim of this study is to present a clinical series of patients with trigeminal neuropathy and their treatment.
Patients And Methods: We present a retrospective study of 15 cases of idiopathic trigeminal neuropathies, with unilateral involvement of 1 or more divisions of the trigeminal nerve. The clinical, radiologic, and laboratory data of the patients, in addition to the treatment and clinical evolution, were reviewed. The patients were followed up for a mean of 34.4 months (range, 12-120 months).
Results: The study consisted of 11 women and 4 men. The numbness was predominantly located in the innervated mental area and extended in some cases to the first and second trigeminal divisions. Seven patients had slight continuous discomfort in association with the numbness, one of whom had added bouts of typical neurogenic pain. Of the 15 cases, 8 (53%) had acute idiopathic trigeminal neuropathies and fully recovered within 3 months and 7 (47%) were chronic cases, without full recovery after 3 months. Mild pain was felt by 57% of the chronic patients and 37% of the acute patients; treatment with amitriptyline achieved complete or partial improvement in over half of these patients.
Conclusion: Of the idiopathic trigeminal neuropathies, half were acute and half were chronic. Mild pain presented more frequently in the chronic patients and was relieved with amitriptyline.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.joms.2009.04.079 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cranial fibrous dysplasia (FD) syndrome is a benign, rare, and idiopathic skeletal disorder characterized by the replacement and expansion of medullary bone by disorganized fibro-osseous tissue. Trigeminal neuralgia (TN) is most commonly caused by vascular compression at the trigeminal nerve root entry zone. Secondary TN caused by cranial FD syndrome is extremely rare.
View Article and Find Full Text PDFBotulinum toxin modulates the blink reflex via the trigeminal afferent system in hemifacial spasm: an early and late-term effect.
Neurol Sci
December 2024
Department of Neurology, Section of Clinical Neurophysiology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Background: There is growing evidence that botulinum neurotoxin (BoNT) can mediate changes at the central level through peripheral mechanisms, leading to alterations in central sensorimotor integration. However, the effect of BoNT on brainstem excitability in patients with hemifacial spasm(HFS) is not yet fully understood, and its long-term effects remain unknown.
Objective: This study aims to investigate the impact of BoNT on the excitability of the facial nucleus in patients with idiopathic HFS.
Pathophysiology of oral lesions subsequent to SARS-CoV-2 vaccination: A systematic review.
J Oral Maxillofac Pathol
October 2024
Kasturba Medical College, Manipal, Karnataka, India.
Amidst worldwide reports of adverse oral lesions subsequent to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, the current systematic review planned to determine the prevalence of adverse oral events in adult individuals (≥18 years) after SARS-CoV-2 vaccination, emphasizing upon the type and dose of vaccine, time of onset, and underlying pathophysiology. The registered protocol (PROSPERO CRD42023421307), conforming with PRISMA guidelines, included an all-inclusive literature search through online databases, consisting of Scopus, PubMed/MEDLINE, Web of Science, Lilacs, Livivo, and PROSPERO, completed on 2 May 2023, followed by assessment of risk of bias by Joana Briggs Institute Evaluation Checklist. Due to the paucity of literature, case reports and case series were included.
View Article and Find Full Text PDFBotulinum Toxin Type A in Trigeminal Neuralgia Treatment: A Case Series and Literature Review.
Cureus
November 2024
Unidade de Neurofisiologia Clínica, Centro Hospitalar Universitário de Lisboa Central, Lisboa, PRT.
Trigeminal neuralgia (TN) stands as a common neuropathic pain disorder. Clinically, it manifests with episodes characterized by unilateral electric shock-like or knife-like pain that can involve one or more divisions of the fifth cranial nerve. Botulinum neurotoxin type A (BoNT-A) is a neurotoxin that has demonstrated analgesic effects in neuropathic pain and positive benefits in the treatment of refractory idiopathic TN.
View Article and Find Full Text PDFWhat Is New and Effective in Treating Refractory Trigeminal Neuralgia?
Cureus
November 2024
Botulinum Toxin Clinic, Gait Analysis Laboratory, Centro De Medicina De Reabilitação De Alcoitão, Lisboa, PRT.
Trigeminal neuralgia (TN) is a severe facial pain disorder characterized by brief, electric shock-like pain triggered by innocuous stimuli, commonly affecting middle-aged women. TN can be classified as classic, secondary, or idiopathic, with the secondary form linked to multiple sclerosis (MS). Treatment typically begins with carbamazepine or oxcarbazepine, but surgical and alternative treatments, including botulinum toxin type A (BoNT-A), may be considered for refractory cases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!